eligibility_summary
Eligible: consenting adults 18–75 with newly diagnosed NHL, ECOG 0–2, ≥1 measurable lesion, ≥3‑mo life expectancy, adequate marrow (ANC ≥1.5 [≥1.0 if BM], PLT ≥75 [≥50], Hb ≥80 [≥75]) and renal/hepatic function (Cr ≤1.5×ULN, AST/ALT ≤2.5× [≤5× if liver], TBil ≤1.5× [≤3×]). Exclude: prior anthracyclines, hypersensitivity, uncontrolled illness, significant cardiac disease, active HBV/HCV, HIV, other active malignancy, CNS lymphoma, pregnant/lactating or no contraception, or per investigator.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Trial tests CMOP±R in newly diagnosed NHL. Drugs and mechanisms (type): • Mitoxantrone hydrochloride liposome—anthracenedione, liposomal cytotoxic chemo, topoisomerase II inhibitor and DNA intercalator causing DNA breaks. • Cyclophosphamide—alkylating nitrogen mustard, DNA crosslinker/cytotoxic. • Vincristine or vindesine—vinca alkaloid, inhibits microtubule polymerization, arresting mitosis. • Prednisone or dexamethasone—glucocorticoid, induces lymphocyte apoptosis, anti-inflammatory. • Rituximab (for CD20+ disease)—chimeric anti-CD20 monoclonal antibody, depletes B cells via ADCC, CDC, and apoptosis. Cells/pathways targeted: proliferating lymphoma cells, B cells expressing CD20, DNA replication/repair (Topo II), DNA integrity (alkylation/crosslinking), mitotic spindle/microtubules, glucocorticoid receptor–mediated apoptosis, and immune effector pathways (Fc/complement) for B-cell clearance.